Chromocell Therapeutics (CHRO): Growth-Adjusted Payback Ratio
Geopolitical instability and component supply chain disruptions create significant risks for Chromocell Therapeutics (CHRO). The PEG ratio visualizes these fluctuations, where the value 0.00 represents the current metric. The market launch of non-opioid analgesics will provide stability, yet a high dependence on the success of ion channel inhibitors maintains a binary vulnerability within the company's development portfolio.
Analytical breakdowns for Chromocell Therapeutics (CHRO)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Capital Chromocell Therapeutics|CHRO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio chromocell.com|CHRO - Company Aggregate Debts|Debts to Book Value Chromocell Therapeutics Corporation|CHRO - Company Long-Term Debt|Company Short-Term Debt Chromocell Therapeutics|Quick Liquidity chromocell.com
- earnings and multiples data:
CHRO - Net Income|Expected Net Income Chromocell Therapeutics|CHRO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Chromocell|CHRO - PEG Multiple|Business Value to Operating Income Before Depreciation Chromocell Therapeutics Corporation|CHRO - Operating profit EBITDA|Net earnings per one share for the last twelve months Chromocell Therapeutics|CHRO - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months chromocell.com|CHRO - Earnings growth in current year|Earnings growth forecast for next year Chromocell Therapeutics
General company analysis:CHRO - Chromocell Therapeutics Corp
Investment interest in Chromocell Therapeutics (CHRO) requires a deep analysis of the ratio between market value and profit dynamics, which this undervaluation-to-growth indicator clearly reflects. The metric compares market capitalization with revenue growth rates, allowing for an assessment of the effectiveness of implementing robotic screening systems and clinical data software processing as drivers for future capital appreciation.
Competitors of Chromocell Therapeutics
BIIB (Biogen Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Growth-Adjusted Payback Ratio RGC|AXSM - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate acadia-pharm.com|Xenon (XENE) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Viking Therapeutics Inc|Price/Earnings to Growth Ratio Supernus Pharma|Price to Earnings Adjusted for Growth Rate Catalyst Corp CPRX|PEG Multiple DNLI|Price/Earnings to Growth Multiple harmonybiosciences.com HRMY|PEG Multiple BHVN (Biohaven)|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI - Price/Earnings to Growth Ratio|PRAX: Price/Earnings to Growth Ratio|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|CBLL (ceribell.com) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple PRTA|ALEC: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple ANNX (Annexon Inc.)|Company Value to Earnings Growth Ratio OMER|PEG Multiple NGNE (Neurogene Inc.)|Growth-Adjusted Payback Ratio ACIU|Voyager Therapeutics, Inc. - PEG Multiple|Price to Earnings Adjusted for Growth Rate Neumora|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Tevogen Bio Inc. - Growth-Adjusted Payback Ratio|ACOG (Alpha Cognition Inc) - PEG Multiple|PEG Multiple cogrx.com|Price/Earnings to Growth Ratio Inhibikase Therapeutics, Inc. (IKT)|SAVA: Market Cap to Earnings and Growth Ratio|PEG Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Earnings Adjusted for Growth Rate|VTGN: Price/Earnings to Growth Multiple|OVID - PEG Multiple|ABOS (Acumen Pharmaceuticals, Inc.) - Price/Earnings to Growth Multiple|CRVO: Company Value to Earnings Growth Ratio|ATHE (Alterity Therapeutics Ltd.) - PEG Multiple|Clene Nanomedicine (CLNN) - Growth-Adjusted Market Cap to Net Income|PEG Multiple PEPG|Price/Earnings to Growth Multiple jupiterneurosciences.com JUNS|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|Growth-Adjusted Market Cap to Net Income Annovis Bio Inc (ANVS)|Grace Tx - PEG Multiple|Firefly Neuro (AIFF) - Price/Earnings to Growth Multiple|KLTO: PEG Multiple|NeuroSense Therapeutics Ltd. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Reviva Pharmaceuticals Holdings, Inc.|MTVA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio NeurAxis, Inc (NRXS)|HSDT - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Passage Bio PASG|NEUP: Growth-Adjusted P/E Ratio|Minerva Neurosciences, Inc. - PEG Multiple|Price to Earnings Adjusted for Growth Rate Athira Pharma Inc|ADXN (Addex Therapeutics, Ltd.) - Price/Earnings to Growth Multiple|Alzamend Neuro (ALZN) - PEG Multiple|Price/Earnings to Growth Ratio Cyclerion Therapeutics Inc.|PTIX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Pasithea Therapeutics (KTTA)|CRGT - Price to Earnings Adjusted for Growth Rate|PEG Multiple ATXI (Avenue Therapeutics, Inc)|BCLI - Price/Earnings to Growth Multiple|Cara Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Payback Ratio ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price/Earnings to Growth Ratio|Longboard Pharmaceuticals Inc - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Marinus|Price to Earnings Adjusted for Growth Rate NKGen Biotech Corp NKGN|Price/Earnings to Growth Ratio NeuroBo Pharmaceuticals (NRBO)|Price/Earnings to Growth Multiple sagerx.com SAGE|Price/Earnings to Growth Ratio Synaptogenix SNPX|Trevena Inc. (TRVN) - Price to Earnings Adjusted for Growth Rate|Vigil Neuro - PEG Multiple|Anew Medical Inc. (WENA) - Price/Earnings to Growth Multiple|CERE: PEG Multiple
